Keywords: Novo Nordisk, Vatreptacpg, Hemophilia, Ph III, Discontinued

Novo Nordisk drops vatreptacog development

Article | 30 September 2012

Print This

Danish insulin giant Novo Nordisk (NOV: N) says that it has decided to discontinue the development of vatreptacog alfa, a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in